{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:27:30Z","timestamp":1779888450812,"version":"3.53.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.contraception.2024.110401","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T10:05:48Z","timestamp":1709201148000},"page":"110401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evaluation of consumer self-selection of a proposed over-the-counter, progestin-only daily oral contraceptive"],"prefix":"10.1016","volume":"133","author":[{"given":"Stephanie","family":"Sober","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Henrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Pradeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Guillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Laurora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Glasier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2024.110401_bib1","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: self-selection studies for nonprescription drug products. April 2013, \u3008https:\/\/www.fda.gov\/media\/81141\/download\u3009; 2013 (accessed December 19, 2022)."},{"key":"10.1016\/j.contraception.2024.110401_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.contraception.2012.01.008","article-title":"Contraindications to progestin-only oral contraceptive pills among reproductive-aged women","volume":"86","author":"White","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110401_bib3","first-page":"1","article-title":"U.S. Medical Eligibility Criteria for Contraceptive Use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2024.110401_bib4","unstructured":"Opill\u00ae tablets (norgestrel tablets)\u00a0[package insert]. Paris, France: Laboratoire HRA Pharma; 2017."},{"key":"10.1016\/j.contraception.2024.110401_bib5","unstructured":"HRA Pharma. Adherence with continuous-dose oral contraceptive: evaluation of self-selection and use (ACCESS). ClinicalTrials.gov Identifier: NCT04112095. \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04112095\u3009; 2022 (accessed September 8, 2023)."},{"key":"10.1016\/j.contraception.2024.110401_bib6","unstructured":"National Cancer Institute. Breast - People alive with cancer (U.S. prevalence) on January 1, 2020, \u3008https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=55&data_type=5&graph_type=12&compareBy=age_range&chk_age_range_1=1&chk_age_range_9=9&chk_age_range_16=16&chk_age_range_62=62&series=9&sex=3&race=1&prev_duration=1&advopt_precision=2&hdn_view=1&advopt_show_apc=on&advopt_display=2#resultsRegion1\u3009 (accessed September 12, 2023)."},{"key":"10.1016\/j.contraception.2024.110401_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.contraception.2022.10.006","article-title":"Modeling the potential benefit of an over-the-counter progestin-only pill in preventing unintended pregnancies in the U.S","volume":"117","author":"Guillard","year":"2023","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110401_bib8","first-page":"391","article-title":"Rapid estimate of adult literacy in medicine: a shortened screening instrument","volume":"25","author":"Davis","year":"1993","journal-title":"Fam Med"},{"key":"10.1016\/j.contraception.2024.110401_bib9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/GCO.0000000000000019","article-title":"Over-the-counter access to oral contraceptives as a reproductive healthcare strategy","volume":"25","author":"Grossman","year":"2013","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.contraception.2024.110401_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.33137","article-title":"Contraceptive use in premenopausal women with early breast cancer","volume":"5","author":"Lambertini","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.contraception.2024.110401_bib11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejogrb.2020.12.035","article-title":"Breast cancer recurrence risk after hormonal contraceptive use in survivors of reproductive age","volume":"258","author":"Ostroot","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2024.110401_bib12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/pds.5431","article-title":"Hormonal contraception use before and after breast cancer diagnosis: a nationwide drug utilization study","volume":"31","author":"M\u00f8rch","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.contraception.2024.110401_bib13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/bjc.1993.175","article-title":"Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism","volume":"67","author":"Catherino","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.contraception.2024.110401_bib14","first-page":"6539","article-title":"Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation","volume":"52","author":"Jeng","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.contraception.2024.110401_bib15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/1538-7445.AM2016-1573","article-title":"The progesterone analogue, norgestrel, impairs tumor immunity and promotes metastatic breast cancer progression","volume":"76","author":"Moreno","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.contraception.2024.110401_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.fertnstert.2007.05.033","article-title":"Use of the levonorgestrel-releasing intrauterine system in breast cancer patients","volume":"90","author":"Trinh","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2024.110401_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1470-2045(18)30059-7","article-title":"Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients","volume":"19","author":"de Haan","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.contraception.2024.110401_bib18","unstructured":"National Cancer Institute. Ovary - People alive with cancer (U.S. prevalence) on January 1, 2020, \u3008https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=61&data_type=5&graph_type=11&compareBy=age_range&chk_age_range_1=1&chk_age_range_9=9&hdn_sex=3&advopt_precision=2&hdn_view=1&advopt_show_apc=on&advopt_display=2#resultsRegion1\u3009\u00a0(accessed September 12, 2023)."},{"key":"10.1016\/j.contraception.2024.110401_bib19","unstructured":"National Cancer Institute. Corpus and uterus, NOS - People alive with cancer (U.S. prevalence) on January 1, 2020, \u3008https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=58&data_type=5&graph_type=11&compareBy=age_range&chk_age_range_1=1&chk_age_range_9=9&hdn_sex=3&advopt_precision=2&hdn_view=1&advopt_show_apc=on&advopt_display=2#resultsRegion1\u3009\u00a0(accessed September 12, 2023)."},{"key":"10.1016\/j.contraception.2024.110401_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpobgyn.2020.05.003","article-title":"Progesterone and endometrial cancer","volume":"69","author":"Gompel","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2024.110401_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3892\/or.2021.8174","article-title":"Hormone therapy for ovarian cancer: emphasis on mechanisms and applications (review)","volume":"46","author":"Li","year":"2021","journal-title":"Oncol Rep"},{"key":"10.1016\/j.contraception.2024.110401_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/andr.12110","article-title":"Male hormonal contraception: looking back and moving forward","volume":"4","author":"Roth","year":"2016","journal-title":"Andrology"},{"key":"10.1016\/j.contraception.2024.110401_bib23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaip.2016.03.003","article-title":"Progestogen hypersensitivity in 24 cases: diagnosis, management, and proposed renaming and classification","volume":"4","author":"Foer","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.contraception.2024.110401_bib24","first-page":"359","article-title":"An epidemiological survey of symptoms of menstrual loss in the community","volume":"54","author":"Shapley","year":"2004","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.contraception.2024.110401_bib25","unstructured":"National Cancer Institute. Cervix uteri - People alive with cancer (U.S. prevalence) on January 1, 2020, \u3008https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=57&data_type=5&graph_type=11&compareBy=age_range&chk_age_range_1=1&chk_age_range_9=9&hdn_sex=3&advopt_precision=2&hdn_view=1&advopt_show_apc=on&advopt_display=2#resultsRegion1\u3009\u00a0(accessed September 12, 2023)."},{"key":"10.1016\/j.contraception.2024.110401_bib26","first-page":"103","article-title":"The frequency of significant pathology in women attending a general gynaecological service for postcoital bleeding","volume":"108","author":"Rosenthal","year":"2001","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2024.110401_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.contraception.2009.01.021","article-title":"Hormonal contraceptive use among women with liver tumors: a systematic review","volume":"80","author":"Kapp","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110401_bib28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.contraception.2009.04.007","article-title":"The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review","volume":"80","author":"Kapp","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110401_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.contraception.2009.01.020","article-title":"WHO provider brief on hormonal contraception and liver disease","volume":"80","author":"Kapp","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110401_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2022.11.006","article-title":"Influence of progestin-only hormonal use on hepatocellular adenomas: a retrospective cohort study","volume":"119","author":"Qureshy","year":"2023","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T19:32:52Z","timestamp":1712259172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782424000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"alternative-id":["S0010782424000544"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110401","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of consumer self-selection of a proposed over-the-counter, progestin-only daily oral contraceptive","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110401"}}